FierceBiotech11d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
BioPharma Dive11d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical ...
Bethesda Magazine10d
Fallen Montgomery County firefighter honored during ride from Baltimore to Pasadena, Md., funeral home
Plus: Rockville gene therapy company inks deal; Pioneering politician from Montgomery County celebrated with portrait ...
Regenxbio, Nippon Shinyaku enter commercialization pact for RGX-121
Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...
bovnews11d
This Biotech Partnership Could Be the Catalyst REGENXBIO (RGNX) Needs—But What’s Next?
The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...
Yahoo Finance11d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical testing. Regenxbio will lead future clinical development of both RGX ...
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku
Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., Ltd. for the development and ...
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...
BioWorld11d
JPM: Sling’s small molecule has success in thyroid eye disease
III study in treating thyroid eye disease. The privately held company posted top-line efficacy and safety results from a phase IIb/III study of its lead candidate, linsitinib, which hits its primary ...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of ...
pharmaphorum1d
Regenxbio expands MPS I gene therapy trial after first look at data
Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...
REGENXBIO partners with Nippon Shinyaku for MPS therapies
REGENXBIO (NASDAQ:RGNX) and Nippon Shinyaku have entered into a partnership for the development and commercialization of REGENXBIO's gene therapies RGX-121 for the treatment of Hunter syndrome, or MPS ...